The Medical Arts Health Research Group - West Vancouver
Welcome,         Profile    Billing    Logout  
 0 Trials 
9 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Riddle, Meghan
TRAILBLAZER-ALZ 6, NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease

Active, not recruiting
3
800
Europe, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
05/24
05/25
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
START, NCT05531656: A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

Recruiting
2
540
US
CT1812, Study Drug Active, Placebo, Matching Placebo
Cognition Therapeutics, National Institute on Aging (NIA), Alzheimer's Clinical Trials Consortium
Early Alzheimer's Disease
04/27
04/27
LINE-AD, NCT04500847: Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD

Recruiting
1
35
US
Emtriva Capsule, Emtricitabine, Placebo, Capsule manufactured to mimic Emtriva
Butler Hospital, Alzheimer's Association, Brown University, The Miriam Hospital
Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Moderate Dementia
03/25
03/25
LEADS, NCT03507257: Longitudinal Early-onset Alzheimer's Disease Study Protocol

Recruiting
N/A
850
Europe, US, RoW
Flortaucipir, 18F-AV-1451 (also known as [F-18]T807 or LY3191748), Florbetaben, AV-45, Neuraceq, Fluorodeoxyglucose, FDG
Indiana University, Alzheimer's Therapeutic Research Institute, National Institute on Aging (NIA), Alzheimer's Association
Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
05/25
05/25
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
12/24
12/24
ADNI4, NCT05617014: Alzheimer's Disease Neuroimaging Initiative 4

Recruiting
N/A
1500
Canada, US
Neuraceq, Florbetaben, Amyvid, Florbetapir, Tauvid, Flortaucipir, 18F-AV-1451, AV-1451, MK-6240, florquinitau F-18, [18F]MK-6240, NAV4694, [18F]NAV4694, [18F]AZD4694, PI-2620, [18F]PI-2620
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment, Alzheimer Disease, Dementia
07/27
07/27

Download Options